Difference between revisions of "NF-kappa-B inhibitor alpha"
m |
m |
||
| Line 29: | Line 29: | ||
| PRDGL''KK''ERLLD | | PRDGL''KK''ERLLD | ||
LHSIL''K''ATNYN | LHSIL''K''ATNYN | ||
| + | |||
PSTRI''QQ''QLGQL | PSTRI''QQ''QLGQL | ||
| + | |||
DCVFGG''Q''RLTL | DCVFGG''Q''RLTL | ||
|- | |- | ||
Revision as of 13:39, 27 March 2008
| Template:Infobox header| NF-kappa-B inhibitor alpha | |
|---|---|
| Substrate peptide name | NF-kappa-B inhibitor alpha |
| Synonyms | I-kappa-B-alpha |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytosol |
| Swissprot ID | P25963 |
| Reactive glutamines | Q266, Q267, Q313 |
| Reactive lysines | K21, K22, K177 |
| Substrate sequence | PRDGLKKERLLD
LHSILKATNYN PSTRIQQQLGQL DCVFGGQRLTL |
| Structure | 1IKN |
| Surface accessibility | ASAView pdf |
| Disorder prediction | IUPred |
| Reference | PMID:16987813 |
| Notes | |
| Template:Infobox header | |
